External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home ACTRIMS Forum 2024
Roche and Genentech at

ACTRIMS Forum 2024

February 29 - March 02
West Palm Beach, Florida
forum.actrims.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
11:00 PM
Duration 2hrs West Palm Beach, Florida
Disease Burden of Multiple Sclerosis in Underserved Populations Across the US in 2019
Anisha M Patel, Elizabeth S Mearns, Stacey Kowal, Katherine L Rosettie, David Jones, Nikki Win
Neuroscience | Multiple Sclerosis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 2hrs West Palm Beach, Florida
Predictors of Utilizing Comprehensive Care Orders in Multiple Sclerosis Care
Kimberly DiMauro, Mengke Du, Elizabeth S. Mearns, Nikki Win, Bryan R. Cobb PhD, Marisa McGinley
Neuroscience | Multiple Sclerosis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 2hrs West Palm Beach, Florida
The Safety Profile of Fenebrutinib in Patients With Multiple Sclerosis Is Consistent With Those In Previously Studied Autoimmune Indications
Jiwon Oh, Anastasiia Raievska, Malgorzata Sierzega, Joao Cerqueira, Claire S. Riley, Maresa Caunt, John N. Ratchford, Alexandra Goodyear, Konstantina Vanevski, Maria Pia Sormani, Gavin Giovanonni
Neuroscience | Multiple Sclerosis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 2hrs West Palm Beach, Florida
Disability Outcomes Among Persons With Multiple Sclerosis Treated With First-Line Ocrelizumab vs. Other Disease-Modifying Therapies
Caroline K Geiger, Fadoua El Moustaid, Katherine L Rosettie
Neuroscience | Multiple Sclerosis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 2hrs West Palm Beach, Florida
One-Year Efficacy and Safety Data Analysis of People With Relapsing Multiple Sclerosis From Kenya Receiving Ocrelizumab in the CHIMES Trial
Dilraj Singh Sokhi, Juzar Hooker, Jacqueline Mavuti, Mitzi J. Williams, Lilyana Amezcua, Jugena Smith, Jinglan Pei, Ibraheem Abioye, and Mansoor Saleh
Neuroscience | Multiple Sclerosis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 2hrs West Palm Beach, Florida
OCARINA Clinical Trial Program, Dose Selection and Non-Inferiority of Ocrelizumab Administered Subcutaneously in Patients With Relapsing Multiple Sclerosis or Primary Progressive Multiple Sclerosis
Newsome SD, Figueiredo C, Wolf C, Clinch S, Kletzl H, Bortolami O, Giacobino C, Shen Y-A, Townsend B, Zecevic D, Centonze D, Bermel R, Krzystanek E, Selmaj K, Goldstick L
Neuroscience | Multiple Sclerosis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.